Let me start with question number one. I'll go to Mr. Lee. He seems to be answering questions, or Ms. Godard, whoever is capable. I just don't want to presuppose.
We've heard from colleagues that Health Canada wouldn't need the supplementary rules provision to take action on pseudoephedrine, which is a precursor to the production of meth. Can you explain what makes pseudoephedrine different from other precursors, and why other legislation couldn't be used in this particular case?